Development of early-stage clinical and pre-clinical assets:

Neurolixis is developing a platform of early-stage drug candidates targeting serious CNS diseases with unmet medical needs and sizeable market opportunity. Compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism" which enables drugs to more precisely target specific brain regions controlling CNS disorders.

NLX-112, is a Phase II-ready drug intended for the treatment of L-DOPA-induced dyskinesia, a side-effect of Parkinson's disease treatment.

NLX-101, is a Phase I drug intended for treatment of Rett's syndrome, a genetically-encoded orphan disorder. Possible utility for treatment-resistant depressive disorders.

NLX-204 is the lead novel chemical entity from the drug discovery program. It is undergoing evaluation as a potential antidepressant or analgesic (non-opioid mechanism).



All drugs or therapies will be subjected to rigorous testing under applicable law and approval by regulatory authorities, including the FDA, prior to marketing and sale.


Please enable the javascript to submit this form

Follow Neurolixis on: